GSK partners with digital health company to advance remote patient monitoring

Pharma News: The digital respiratory devices market may hit $405 million in value by 2030, growing globally at a 27.31% CAGR from 2021. Increasing prevalence of respiratory diseases, increasing adoption of digital technology among individuals and treatment satisfaction with inhaled therapy are fuelling the growth of the market.

Australia’s Adherium, a leader in respiratory ehealth, has received Food and Drug Administration (FDA) clearance to market an application connecting GlaxoSmithKline’s (GSK) Ellipta inhaler users with Adherium’s next generation Hailie sensor with physiological parameters for monitoring asthma and chronic obstructive pulmonary disease (COPD) medication use.

Following market clearance of the Hailie sensor with physiological parameters for AstraZeneca’s Symbicort MDI inhaler last September, Adherium’s latest Hailie sensor is designed for use with the GSK’s Breo, Anoro, Incruse, Trelegy and Arnuity Ellipta dry powder inhalers (DPIs) and captures physiological parameters, including inhalation duration, volume, and peak inhalation flow. This new series of devices provide a superior perspective into inhaler usage and technique giving patients and doctors immediate, real-time feedback thereby allowing patients to improve their quality of life and enabling physicians to enhance patient care by capturing clinical data supporting patient management and treatment.

Rick Legleiter, Adherium CEO, commented “Executing our strategy and once again delivering on our product roadmap milestones, we continue to demonstrate Adherium is the global partner of choice for remote patient monitoring.

“The clearance to connect Ellipta inhaler users with our new, next generation Hallie platform represents another major step forward in our drug agnostic strategy. In addition, this further broadens the pathway for doctors and hospital groups in the US to access reimbursement for remote monitoring of patients prescribed Asthma and COPD medications on our path toward building a sustainable, cash flow positive business.”

Tara Creaven-Capasso, Adherium’s Vice President Quality, Regulatory and Clinical Affairs, said “We enhance healthcare outcomes by improving quality of life for patients around the world and reduce emergency department visits and hospital admissions and the economic burden of chronic respiratory diseases.”

Adherium continues its global expansion strategy to extend its digital technological innovations to enable reimbursement on 18 of the top 20 US branded inhaler medications in 2023.